KMBC: New drug shows promise for patients with common genetic heart condition
A new drug is showing tremendous promise for patients with a common genetic heart condition, called hypertrophic cardiomyopathy.
Dr. John Spertus, Clinical Director of Outcomes Research at Saint Luke's Mid America Heart Institute, led phase 3 of the EXPLORER-HCM Clinical Trial, which evaluated how the medication impacted patients' quality of life.
KMBC talked to Dr. Spertus about the exciting results and one participant, Gary Frericks, who says it has changed his life.
Watch the full story below.